Business Context and Reporting Period
Company: MDB Capital Holdings, LLC (MDBH)
Reporting Period: Fiscal Year Ended December 31, 2024
Business Model: MDB operates as a holding company and "public venture capital" platform. It co-founds and finances early-stage technology and life sciences companies ("partner companies") and provides support through its subsidiaries: Public Ventures (a broker-dealer and clearing firm) and PatentVest (an intellectual property service provider). Key partner companies include MDB Minnesota One (M1), focused on anti-senescence therapeutics, and eXoZymes (formerly Invizyne), a synthetic biology company.
Key Event: On November 14, 2024, eXoZymes completed its Initial Public Offering (IPO). MDB's ownership diluted from approximately 60% to 47%, resulting in the deconsolidation of eXoZymes from MDB's financial statements. The investment is now accounted for using the equity method.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Total Operating Income | $2,157,273 | $5,995,027 |
| Total Operating Costs | $30,789,483 | $14,498,171 |
| Net Operating Loss | $(28,632,210) | $(8,503,144) |
| Gain on Deconsolidation of Subsidiary | $39,307,217 | $0 |
| Net Income (Loss) Attributable to MDB | $11,692,091 | $(6,968,817) |
| Cash and Cash Equivalents | $20,437,492 | $6,109,806 |
| Total Assets | $71,976,399 | $42,985,279 |
| Total Liabilities | $1,903,065 | $5,665,177 |
| Working Capital | $19,822,938 | $28,925,236 |
Segment Performance:
- Broker Dealer & IP Service: Reported a net loss of $(6,139,990) in 2024 compared to net income of $473,087 in 2023. Fee income decreased 47.5% to $2.22 million due to reduced investment banking activity.
- Technology Development: Reported a net loss of $(4,904,524) in 2024 (excluding the deconsolidation gain) compared to $(1,359,046) in 2023. This segment includes M1 and the pre-deconsolidation results of eXoZymes.
Material Changes vs. Prior Period
- Deconsolidation of eXoZymes: The most significant change was the deconsolidation of eXoZymes following its IPO. This resulted in a one-time non-cash gain of $39.3 million and the removal of eXoZymes' assets, liabilities, and operating results from the consolidated statements after November 14, 2024.
- Operating Loss Expansion: The consolidated net operating loss widened significantly to $(28.6) million from $(8.5) million. This was driven by a 132.5% increase in compensation expenses (largely due to stock-based compensation) and a 177.9% increase in R&D costs.
- Revenue Decline: Total operating income dropped 64.0% year-over-year. Fee income from the broker-dealer subsidiary fell by $2.0 million, and unrealized gains on investment securities turned into a loss of $(274,835) compared to a gain of $1.5 million in 2023.
- Liquidity Position: Cash and cash equivalents increased by 234.5% to $20.4 million, primarily due to the maturity and sale of U.S. Treasury Bills and the cash proceeds from the eXoZymes IPO (reflected in the equity method investment valuation).
Guidance, Outlook, Risks, and Contingencies
Outlook and Strategy: Management continues to focus on the "Big Idea Pipeline" to identify and fund early-stage companies. The company plans to maintain its broker-dealer and self-clearing operations while supporting the development of M1's anti-senescence platform. No specific financial guidance was provided for future periods.
Material Weakness in Internal Controls: Management identified a material weakness in internal control over financial reporting related to the proper identification and accounting treatment of the deconsolidation of eXoZymes. A remediation plan is in place, with full implementation expected by the end of Q2 2025.
Key Risks:
- Regulatory Review: Public Ventures is currently subject to a review of past broker-dealer activities. The outcome is unknown but could result in fines or limitations on activity.
- Concentration Risk: The company holds a significant equity method investment in eXoZymes ($41.8 million). Fluctuations in eXoZymes' stock price or performance will materially impact MDB's financial results.
- Geopolitical/Sanctions Risk: MDB outsources back-office services to a Nicaraguan entity (MDB Capital S.A.). Executive Orders and sanctions regarding Nicaragua could disrupt these services or increase costs.
- Partner Company Viability: M1 is in the pre-clinical stage with no commercial products. Failure to achieve clinical milestones or secure funding could impair the value of this investment.
- Cybersecurity: As a financial institution and data handler, MDB faces risks from cyberattacks, which could disrupt operations or lead to liability.
Investor Verification Checklist
- Deconsolidation Accounting: Verify the calculation of the $39.3 million gain on deconsolidation and the fair value of the retained 47% interest in eXoZymes.
- Internal Control Remediation: Monitor the progress of the remediation plan for the material weakness identified regarding the eXoZymes deconsolidation.
- Regulatory Status: Track the status of the regulatory review of Public Ventures' past activities and any potential penalties.
- Nicaraguan Operations: Assess the impact of U.S. sanctions on the company's ability to utilize its outsourced service provider in Nicaragua.
- M1 Milestones: Review the progress of MDB Minnesota One's pre-clinical development and its ability to meet funding requirements without further dilution.
- Stock-Based Compensation: Analyze the sustainability of the high compensation costs driven by RSU grants and their impact on future cash burn.